Complete Response of Metastatic Papillary Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus to Nivolumab Plus Cabozantinib

Overview

Journal IJU Case Rep

Date 2023 Nov 6

PMID 37928303

Authors

Michikata Hayashida

Yuji Miura

Takeshi Yamaguchi

Makoto Tanaka

Taro Yamanaka

Kohji Takemura

Suguru Oka

Kazushige Sakaguchi

Shinji Ito

Shinji Urakami

Affiliations

Soon will be listed here.

Abstract

Introduction: The effectiveness of nivolumab plus cabozantinib for metastatic papillary renal cell carcinoma with inferior vena cava tumor thrombus remains unclear.

Case Presentation: A 77-year-old male was diagnosed with right papillary renal cell carcinoma with a metastatic lesion on Gerota's fascia, lymph node metastasis, and inferior vena cava tumor thrombus. He was treated with nivolumab plus cabozantinib. As all lesions regressed enough to permit complete resection, radical nephrectomy, thrombectomy, and retroperitoneal lymph node dissection were performed. No viable malignant cells were identified histopathologically. Despite the discontinuation of nivolumab plus cabozantinib, there has been no recurrence for 9 months.

Conclusion: Nivolumab plus cabozantinib has effectiveness for metastatic papillary renal cell carcinoma with inferior vena cava tumor thrombus.

Citing Articles

A case of papillary renal cell carcinoma with para-aortic lymph node metastasis that was completely resectable after treatment with combination therapy comprising lenvatinib and pembrolizumab and robot-assisted radical nephrectomy.

Hosoi T, Yoshioka S, Hiraguri A, Kirihana Y, Koguchi T, Tamaki M IJU Case Rep. 2025; 8(2):150-153.

PMID: 40034897 PMC: 11872193. DOI: 10.1002/iju5.12830.

References

Choueiri T, Powles T, Burotto M, Escudier B, Bourlon M, Zurawski B . Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021; 384(9):829-841. PMC: 8436591. DOI: 10.1056/NEJMoa2026982. View

Rao Ullur A, Cote G, Pelletier K, Kitchlu A . Immunotherapy in oncology and the kidneys: a clinical review of the evaluation and management of kidney immune-related adverse events. Clin Kidney J. 2023; 16(6):939-951. PMC: 10229281. DOI: 10.1093/ckj/sfad014. View

Reimers M, Figenshau R, Kim E, Tucker J, Kasten N, Khan A . Elective Cytoreductive Nephrectomy After Checkpoint Inhibitor Immunotherapy in Patients With Initially Unresectable Metastatic Clear Cell Renal Cell Carcinoma. Clin Genitourin Cancer. 2020; 18(5):361-366. PMC: 7541406. DOI: 10.1016/j.clgc.2020.04.002. View

Mejean A, Ravaud A, Thezenas S, Colas S, Beauval J, Bensalah K . Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018; 379(5):417-427. DOI: 10.1056/NEJMoa1803675. View

Hayashida M, Miura Y, Noda T, Yamanaka T, Tanaka N, Yasuoka S . Complete response of metastatic renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus ipilimumab. IJU Case Rep. 2022; 5(4):268-272. PMC: 9249646. DOI: 10.1002/iju5.12452. View

Pignot G, Thiery-Vuillemin A, Walz J, Lang H, Bigot P, Werle P . Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?. Eur Urol. 2020; 77(6):761-763. DOI: 10.1016/j.eururo.2019.12.018. View

Mcdermott D, Lee J, Ziobro M, Suarez C, Langiewicz P, Matveev V . Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. J Clin Oncol. 2021; 39(9):1029-1039. PMC: 8078262. DOI: 10.1200/JCO.20.02365. View

Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen J, Blank C . Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol. 2018; 5(2):164-170. PMC: 6439568. DOI: 10.1001/jamaoncol.2018.5543. View

Albiges L, Gurney H, Atduev V, Suarez C, Climent M, Pook D . Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2023; 24(8):881-891. DOI: 10.1016/S1470-2045(23)00276-0. View

10.

Bakouny Z, El Zarif T, Dudani S, Wells J, Gan C, Donskov F . Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2022; 83(2):145-151. DOI: 10.1016/j.eururo.2022.10.004. View

11.

Neves R, Zincke H . Surgical treatment of renal cancer with vena cava extension. Br J Urol. 1987; 59(5):390-5. DOI: 10.1111/j.1464-410x.1987.tb04832.x. View

12.

Martinez Chanza N, Xie W, Bilen M, Dzimitrowicz H, Burkart J, Geynisman D . Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol. 2019; 20(4):581-590. PMC: 6849381. DOI: 10.1016/S1470-2045(18)30907-0. View

13.

Harshman L, Yu R, Allen G, Srinivas S, Gill H, Chung B . Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). Urol Oncol. 2011; 31(3):379-85. DOI: 10.1016/j.urolonc.2011.01.005. View

14.

Lee C, Voss M, Carlo M, Chen Y, Zucker M, Knezevic A . Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. J Clin Oncol. 2022; 40(21):2333-2341. PMC: 9287282. DOI: 10.1200/JCO.21.01944. View

15.

Pignot G, Thiery-Vuillemin A, Albiges L, Walz J, Lang H, Balssa L . Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma. Eur Urol Oncol. 2022; 5(5):577-584. DOI: 10.1016/j.euo.2022.07.002. View

16.

Mielczarek L, Brodziak A, Sobczuk P, Kawecki M, Cudnoch-Jedrzejewska A, Czarnecka A . Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function. Cancer Chemother Pharmacol. 2021; 87(6):723-742. PMC: 8110505. DOI: 10.1007/s00280-021-04260-y. View

17.

Hagimoto H, Kashima S, Doi K, Nakayama S, Sano T, Imai S . Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma. IJU Case Rep. 2020; 3(6):287-290. PMC: 7609183. DOI: 10.1002/iju5.12220. View

18.

Pal S, Tangen C, Thompson Jr I, Balzer-Haas N, George D, Heng D . A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021; 397(10275):695-703. PMC: 8687736. DOI: 10.1016/S0140-6736(21)00152-5. View